Uniqure N V 's Cash & cash equivalent grew by 74.47 % in the Q1 2026 sequentially, while Current Liabilities decreased, this led to improvement in Uniqure N V 's Quick Ratio to 2.36, Quick Ratio remained below Uniqure N v average.

Within Major Pharmaceutical Preparations industry 265 other companies have achieved higher Quick Ratio than Uniqure N V in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 993 to 1043.

Explain Quick Ratio?
How much Cash & cash equivalents QURE�s has?
What are QURE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

QURE Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1
Y / Y Current Liabilities Change	81.52 %	72.61 %	50.25 %	-59.16 %	-41.21 %
Y / Y Cash & cash equivalent Change	-35.55 %	-49.51 %	137.28 %	-11.84 %	-10.63 %
Quick Ratio MRQ	2.36	1.28	5.93	6.86	6.66
QURE's Total Ranking	# 1043	# 993	# 444	# 447	# 431
Seq. Current Liabilities Change	-5.92 %	-37.48 %	171.83 %	13.52 %	-10.53 %
Seq. Cash & cash equivalent Change	74.47 %	-86.56 %	135.27 %	16.83 %	36.68 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 266
Healthcare Sector	# 446
Overall Market	# 1043

Quick Ratio Statistics
High	Average	Low
24.46	9.81	1.28
(Sep 30 2019)		(Dec 31 2025)

Financial Statements
Uniqure N V 's Current Liabilities	$ 59 Millions	Visit QURE's Balance sheet
Uniqure N V 's Cash & cash equivalent	$ 140 Millions	Visit QURE's Balance sheet
Source of QURE's Sales		Visit QURE's Sales by Geography

Cumulative Uniqure N V 's Quick Ratio

QURE's Quick Ratio for the trailling 12 Months

QURE Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	14.6 %	-6.56 %	-25.76 %	-36.41 %	-6.37 %
Y / Y Cash & cash equivalent TTM Growth	16.97 %	21.97 %	19.83 %	-12 %	-25.4 %
Quick Ratio TTM	4.12	4.92	5.94	5.09	4.04
Total Ranking TTM	# 2962	# 2090	# 2662	# 3144	# 3018
Seq. Current Liabilities TTM Growth	11.4 %	12.8 %	19.45 %	-23.66 %	-9.16 %
Seq. Cash & cash equivalent TTM Growth	-6.73 %	-6.41 %	39.18 %	-3.72 %	-2.74 %

Quick ratio ranking by company, industry and sector >> Back to QURE Financial Strength Comparisons >> Go to Compare QURE Quick Ratio to its Competitors

News about Uniqure N v Quick Ratio

UniQure N.V. Navigating Market Challenges Amid Devastating Conditions,

Reasons Behind UniQure N.V.’s Recent Stock Performance: A Month Overview In a month characterized by mixed market conditions, shares of UniQure N.V. have shown a divergence from broader trends. While the stock has faced struggles, the underlying factors that have shaped its performance warrant careful inspection. In this article, we will examine the recent movements of UniQure s shares, potential market influences, and company-specific news that may explain the company s situation this month.Throughout July 2024, the financial landscape has been tumultuous, marked particularly by the start of the 2024 Olympic Games in Paris. This month commenced with a wave of enthusiasm surrounding the Olympics the unique opening ceremony on the Seine River was a historic moment and drew attention worldwide, bolstering public interest in associated events. However, the exuberance of the Olympics did not translate uniformly across all sectors, including healthcare and biotech, where UniQure operates. The technology and entertainment sectors often garner a more immediate investor attention during such high-profile events, overshadowing the subtle yet significant developments in biopharmaceuticals like those spearheaded by UniQure.

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2026 to $59.20 millions, cumulative Quick Ratio decreased to 4.12 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 397 other companies have achieved higher Quick Ratio than Uniqure N V . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2090 to 2962.

Explain Quick Ratio?
How much Cash & cash equivalents QURE�s has?
What are QURE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 398
Healthcare Sector	# 809
Within the Market	# 2962

trailing twelve months Quick Ratio Statistics
High	Average	Low
13.79	7.81	3.57
(Mar 31 2022)		(Sep 30 2024)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Azitra Inc	6.49	$ 10.051 Millions	$ 1.550 Millions
Sionna Therapeutics Inc	6.48	$ 63.324 Millions	$ 9.776 Millions
Assembly Biosciences Inc	6.47	$ 226.601 Millions	$ 34.997 Millions
Renovorx Inc	6.44	$ 12.362 Millions	$ 1.920 Millions
Opus Genetics Inc	6.42	$ 59.959 Millions	$ 9.340 Millions
Amarin Corp Plcuk	6.40	$ 308.023 Millions	$ 48.153 Millions
Briacell Therapeutics Corp	6.35	$ 22.804 Millions	$ 3.590 Millions
Grace Therapeutics Inc	6.35	$ 16.977 Millions	$ 2.673 Millions
Annexon Inc	6.26	$ 225.025 Millions	$ 35.937 Millions
Tonix Pharmaceuticals Holding Corp	6.26	$ 185.470 Millions	$ 29.647 Millions
Arcturus Therapeutics Holdings Inc	6.15	$ 211.375 Millions	$ 34.369 Millions
Zentalis Pharmaceuticals Inc	6.01	$ 211.758 Millions	$ 35.236 Millions
Camp4 Therapeutics Corporation	5.97	$ 99.209 Millions	$ 16.624 Millions
Rocket Pharmaceuticals Inc	5.90	$ 144.379 Millions	$ 24.466 Millions
Bridgebio Oncology Therapeutics Inc	5.83	$ 252.275 Millions	$ 43.260 Millions
Actinium Pharmaceuticals Inc	5.73	$ 42.132 Millions	$ 7.349 Millions
Kura Oncology Inc	5.72	$ 580.823 Millions	$ 101.496 Millions
Catalyst Pharmaceuticals Inc	5.71	$ 755.859 Millions	$ 132.398 Millions
Cervomed Inc	5.69	$ 12.924 Millions	$ 2.272 Millions
Viking Therapeutics Inc	5.67	$ 602.964 Millions	$ 106.325 Millions
Kala Bio inc	5.63	$ 8.764 Millions	$ 1.557 Millions
Barinthus Biotherapeutics Plc	5.49	$ 65.858 Millions	$ 12.001 Millions
Maia Biotechnology Inc	5.44	$ 34.413 Millions	$ 6.322 Millions
Arrowhead Pharmaceuticals Inc	5.40	$ 1,595.574 Millions	$ 295.220 Millions
Genprex Inc	5.38	$ 18.049 Millions	$ 3.354 Millions
Arvinas Inc	5.31	$ 614.900 Millions	$ 115.900 Millions
Kiora Pharmaceuticals Inc	5.29	$ 13.872 Millions	$ 2.620 Millions
Talphera Inc	5.24	$ 21.108 Millions	$ 4.025 Millions
Dogwood Therapeutics inc	5.17	$ 13.228 Millions	$ 2.560 Millions
Stablecoin Development Corporation	5.15	$ 18.405 Millions	$ 3.576 Millions

Date modified: 2026-07-07T12:44:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.